Holy Stone Healthcare
Holy Stone Healthcare is dedicated to developing lifesaving therapeutics and targeted delivery technologies to improve patients' quality of life worldwide. Their mission is to create innovative hyaluronic acid-based therapeutic products to address unmet clinical needs with superior tolerability and efficacy.
Industries
Nr. of Employees
Very Large (1000+)
Holy Stone Healthcare
4F, No. 88, Sec. 1, Neihu Rd., Neihu Dist. Taipei 11493, Taiwan
Patents
Method for improving substitution rate and/or substitution efficiency of hyaluronan-drug conjugates
US-11458204-B2
View DetailsCompound of glycosaminoglycan and its fabrication method as well as application
US-11229665-B2
View DetailsCompound of glycosaminoglycan and its fabrication method as well as application
US-10342878-B2
View Details
Method for improving substitution rate and/or substitution efficiency of hyaluronan-drug conjugates
US-11458204-B2
View DetailsCompound of glycosaminoglycan and its fabrication method as well as application
US-11229665-B2
View DetailsCompound of glycosaminoglycan and its fabrication method as well as application
US-10342878-B2
View DetailsProducts
IBD98-M
An oral delayed-release capsule combining hyaluronic acid and mesalamine designed for targeted colonic delivery to treat ulcerative colitis.
CA102N
A hyaluronic acid–conjugated small-molecule conjugate targeting CD44-overexpressing solid tumors with dual-pathway (PI3K/mTOR + MAPK) activity; evaluated in clinical and preclinical studies.
ND108E
A CNS-targeted HA conjugate developed for Alzheimer’s disease aiming to restore cognition by reducing amyloid/tau pathology and promoting synaptic recovery in preclinical models.
AMD112
A non-invasive HA-conjugated small-molecule therapy intended for wet age-related macular degeneration, designed for oral or topical administration with CD44-mediated retinal targeting.
HA-based RNA delivery system
Hyaluronic-acid-based nanoparticle platform engineered for delivery of mRNA, siRNA, and other nucleic acids with CD44 targeting and reduced immunogenicity relative to lipid nanoparticles.
IBD98-M
An oral delayed-release capsule combining hyaluronic acid and mesalamine designed for targeted colonic delivery to treat ulcerative colitis.
CA102N
A hyaluronic acid–conjugated small-molecule conjugate targeting CD44-overexpressing solid tumors with dual-pathway (PI3K/mTOR + MAPK) activity; evaluated in clinical and preclinical studies.
ND108E
A CNS-targeted HA conjugate developed for Alzheimer’s disease aiming to restore cognition by reducing amyloid/tau pathology and promoting synaptic recovery in preclinical models.
AMD112
A non-invasive HA-conjugated small-molecule therapy intended for wet age-related macular degeneration, designed for oral or topical administration with CD44-mediated retinal targeting.
HA-based RNA delivery system
Hyaluronic-acid-based nanoparticle platform engineered for delivery of mRNA, siRNA, and other nucleic acids with CD44 targeting and reduced immunogenicity relative to lipid nanoparticles.
Services
Design and execution support for Phase I and Phase II clinical studies, preparation of clinical study reports, and coordination with regulatory authorities for trial approvals.
Pilot-scale GMP manufacturing and analytical support for clinical materials, including formulation development and manufacturing of delayed-release pellets for clinical supply.
Execution of in vivo efficacy, pharmacology, and mechanistic studies in oncology and CNS models, plus support for translational endpoints and imaging-based PD assessment.
Design and execution support for Phase I and Phase II clinical studies, preparation of clinical study reports, and coordination with regulatory authorities for trial approvals.
Pilot-scale GMP manufacturing and analytical support for clinical materials, including formulation development and manufacturing of delayed-release pellets for clinical supply.
Execution of in vivo efficacy, pharmacology, and mechanistic studies in oncology and CNS models, plus support for translational endpoints and imaging-based PD assessment.
Expertise Areas
- Targeted drug delivery
- Hyaluronic acid therapeutics
- Oncology drug development
- Gastrointestinal therapeutics and IBD
Key Technologies
- Hyaluronic acid (HA) drug conjugation
- Polymer-drug conjugates (PDC)
- HA-based nanoparticles for RNA delivery
- CD44 receptor-targeted delivery
News & Updates
Holy Stone Healthcare presented its proprietary HylX drug delivery platform at SDDS 2025 in Kobe, Japan.
Data presented by Dr. Eskouhie Tchaparian showed CA102N's activity in pancreatic cancer models, demonstrating tumor growth inhibition and potential for FDA orphan drug approval.
ND108E's potential to restore cognitive function in Alzheimer's disease was published, marking a significant step in disease-modifying therapy.
The company was granted approval to evaluate CA102N combined with TAS-102 in a Phase 2 trial for mCRC.
The company's novel targeting polymeric drug delivery system received recognition for innovation.
The patented invention for treating inflammatory bowel disease received a silver award.
Holy Stone Healthcare presented its proprietary HylX drug delivery platform at SDDS 2025 in Kobe, Japan.
Data presented by Dr. Eskouhie Tchaparian showed CA102N's activity in pancreatic cancer models, demonstrating tumor growth inhibition and potential for FDA orphan drug approval.
ND108E's potential to restore cognitive function in Alzheimer's disease was published, marking a significant step in disease-modifying therapy.
The company was granted approval to evaluate CA102N combined with TAS-102 in a Phase 2 trial for mCRC.
The company's novel targeting polymeric drug delivery system received recognition for innovation.
The patented invention for treating inflammatory bowel disease received a silver award.